ClinicalTrials.gg
Active, not recruitingNCT06914895SURPASS-T1D-1Updated May 12, 2026

A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight

A Phase 3 interventional study of Tirzepatide and Placebo in Type 1 Diabetes, Obesity and Overweight, sponsored by Eli Lilly and Company. Active, not recruiting at 146 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-12.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
905
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 75 studies in Diabetes Mellitus, Type 1 by Eli Lilly and Company — 4 open to participants now, 6 under way, 4 of them phase 3. Diabetes Mellitus, Type 1 · Eli Lilly and Company.

Planned enrollment
3rd of 72
905 · median 62
Started
2025
with 2 others
Phase 3
23 of 75
2 open now
Registered
70th of 75
by date

Among the 75 studies in Diabetes Mellitus, Type 1 by Eli Lilly and Company, this one is the 3rd largest by planned enrollment of the 72 interventional ones that give a count, is one of 3 that started in 2025, is one of 23 in phase 3, and was the 70th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

4 of the 75 studies in Diabetes Mellitus, Type 1 by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Diabetes Mellitus, Type 1 by Eli Lilly and Company, or all of them as a file.
02

Study summary

The main purpose of this study is to find out how well and how safely tirzepatide works in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 49 weeks.

03

Conditions studied

  • Type 1 Diabetes
  • Obesity
  • Overweight
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have type 1 diabetes and on insulin treatment for at least one year prior to screening
  • Have an value of 7.0% to 10.5% inclusive, at screening
  • Have a (BMI) of ≥25 kilograms per square meter (kg/m2) at screening
  • Are of stable weight for at least 90 days prior to screening and agree to not start an intensive diet or exercise program during the study

Exclusion criteria

Exclusion Criteria:

  • Have experienced two or more events requiring hospitalization due to poor glucose control (hyperglycemia or (diabetic ketoacidosis (DKA)) during the period of 180 days prior to screening and until randomization.
  • Have experienced one or more events of severe hypoglycemia during the period of 90 days prior to screening and until randomization.
  • Are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema
  • Have had chronic or acute pancreatitis
  • Have used any weight loss drugs or alternative remedies, including herbal or nutritional supplements, within 90 days prior to screening
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
905 participants (estimated)

Study arms

  • Experimental
    Tirzepatide Dose 1

    Participants will receive tirzepatide subcutaneously (SC)

    Drug: Tirzepatide

  • Experimental
    Tirzepatide Dose 2

    Participants will receive tirzepatide SC

    Drug: Tirzepatide

  • Experimental
    Tirzepatide Dose 3

    Participants will receive tirzepatide SC

    Drug: Tirzepatide

  • Experimental
    Tirzepatide Dose 4

    Participants will receive tirzepatide SC

    Drug: Tirzepatide

  • Placebo comparator
    Placebo

    Participants will receive placebo SC

    Drug: Placebo

Interventions

  • Administered SC

    Also known as: LY3298176

  • DrugPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Hemoglobin A1c (HbA1c)

    Time frame: Baseline, Week 40

Secondary outcomes

  1. Percentage of Time Continuous Glucose Monitor (CGM) Glucose Values are Between 70 and 180 milligrams per deciliter (mg/dL) (3.9 and 10.0 millimoles per liter (mmol/L) Inclusive, Per Day

    Time frame: Within 30 days prior to Week 40

  2. Change from Baseline in Body Weight

    Time frame: Baseline, Week 40

  3. Percent Change from Baseline in Body Weight

    Time frame: Baseline, Week 40

  4. Percentage of Participants with ≥5% Body Weight Reduction

    Time frame: Baseline, Week 40

  5. Percentage of Participants with ≥10% Body Weight Reduction

    Time frame: Baseline, Week 40

  6. Percentage of Participants with ≥15% Body Weight Reduction

    Time frame: Baseline, Week 40

  7. Change from Baseline in Waist Circumference

    Time frame: Baseline, Week 40

  8. Change from Baseline in Systolic Blood Pressure (SBP)

    Time frame: Baseline, Week 40

  9. Percent Change from Baseline in Fasting Triglycerides

    Time frame: Baseline, Week 40

  10. Percent Change from Baseline in Fasting Non-High-Density Lipoprotein (non-HDL) Cholesterol

    Time frame: Baseline, Week 40

  11. Percent Change from Baseline in Total Daily Insulin Dose

    Time frame: Baseline, Week 40

  12. Percent Change from Baseline in High-Sensitivity C-Reactive Protein (hsCRP)

    Time frame: Baseline, Week 40

  13. Change from Baseline in EQ-5D-5L

    Time frame: Baseline, Week 40

07

Study locations

146 sites

Showing the first 100 of 146 sites across 12 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Nov 2026, 19 months after the start.

Of 79 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 24. This study's planned 19 months is above that.

Counting every sponsor, half of 108 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2025
First posted
Apr 6, 2025
StartActual
Apr 25, 2025
Primary completionEst.
Nov 2026
CompletionEst.
Dec 2026
Last update
May 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06914895
Responsible party
Sponsor
First posted
Apr 6, 2025
Start date
Apr 25, 2025
Primary completion
Nov 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
May 12, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion